Updated 03/15/2016 KATHERINE JEAN WALSH, M.D.

Transcription

1 NAME: KATHERINE JEAN WALSH, M.D. Office Address A350A Starling Loving Hall 320 West 10 th Avenue Columbus, OH Office Phone Fax Cell Phone EDUCATION: University of Florida, B.S. Interdisciplinary Biomedical Science (Junior Honors Medical Program), Highest Honors, 5/ University of Florida, MD, 7-year combined B.S/MD, 5/2004 POSTDOCTORAL TRAINING: Internship and Residency in Internal Medicine, University of Florida, Gainesville, FL Chief Resident, Internal Medicine, University of Florida, Gainesville, FL Fellowship in Hematology/Oncology, Duke University, Durham, NC ( : T32 Training Grant at Duke University) LICENSURE AND CERTIFICATION: 2012 American Board of Internal Medicine/Certified Medical Oncology 2011 American Board of Internal Medicine/Certified Hematology 2011 Ohio State License 2008 North Carolina State License 2007 American Board Internal Medicine/Certified Internal Medicine 2007 Georgia State License- inactive ACADEMIC APPOINTMENTS: 2011 Present Assistant Professor of Clinical Internal Medicine, Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH AWARDS AND HONORS: 2014 Selected to be an Expert Educator for LSI Part 2 Curriculum beginning July AAMC Early Career Women Faculty Development Seminar (Selected by competitive application process) 2013 Associate Clerkship Director for the Inpatient Internal Medicine Clerkship (July 2013-June 2014) 2013 Expert Educator for the Inpatient Internal Medicine Clerkship (July June 2014) 2013 Faculty Advisor, Duke Hematology/Oncology Fellowship Research Retreat 2012 Young Investigator Travel Support from the MDS&AA International Foundation T32 Grant during fellowship at Duke University (Hematology) 2007 Leighton Cluff Award, University of Florida, Department of Medicine (awarded to the senior resident who best represents the qualities of the Former chairman of leadership and dedication to medicine) 2007 Excellence in Teaching, University of Florida, College of Medicine 2006 Chapman Chapter of the Gold Humanism Honor Society Inductee, University of Florida, Inducted as a Resident 2005 Excellence in Ambulatory Care Award, University of Florida, Department

2 of Medicine PROFESSIONAL SOCIETIES: 2013 Association of American Medical Colleges Group on Women in Medicine and Science 2007 American Society of Hematology 2007 American Society of Clinical Oncology 2007 Alpha Omega Alpha 2006 American College of Physicians 2000 American Medical Association TEACHING: Associate Clerkship Director for the Inpatient Internal Medicine Clerkship (July 2013-June 2014) Expert Educator for the Inpatient Internal Medicine Clerkship (July June 2014) Medicine Mentor, Third Year Medical Student Internal Medicine Clerkship, OSU 2013 Second year medical student ICM preceptor (4/26/13) 2011-present Ward attending 3 months per year with teaching responsibilities for 2011-present housestaff that are rotating on the service Clinical attending weekly with teaching responsibilities for housestaff rotating through clinic Small Group Leader, Evidence Based Medicine Series, University of Florida 2008 Ward attending, Malcom Randall VA Medical Center, Gainesville FL Course Instructor, Physician Assistant Hospital Practicum, University of Florida 2003 Teaching Assistant, Clinical Human Anatomy, University of Florida COMMITTEE ACTIVITY 2012-present 2012-present OSU Student Review Committee (Medical School) OSU Student Education Committee (Medical School) American Society of Hematology Government Affairs Committee ACP State Committee for Health and Public Policy Member OSU Acute Leukemia Quality Committee and Sepsis Working Group Member OSU CSRC Committee PUBLICATIONS (Hematology): 1. Walsh KJ, Al-Quran S, Li Y, Braylan RC, Lynch JW Jr. Discordant Expression of CD20 by Flow Cytometry and Immunohistochemistry in a Patient Responding to Rituximab: An Unusual Mechanism Clinical Lymphoma and Myeloma. Jan; 7(4): Rizzieri D and Walsh K. Chemoimmunotherapy s Potential to Impact Paroxysmal Nocturnal Hemoglobinuria. Clinical Advances in Hematology and Oncology Feb;10(2): Dave SS and Walsh K. Chapter 65: Lymphomas for Genomic and Personalized Medicine. Edited by Huntington Willard and Geoffrey Ginsburg. November Zhang J, Grubor V, Love CL, Banerjee A. Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, His ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Lutfig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Proc Natl Acad Sci U S A Jan 22;110(4): Walsh K, McKinney MS, Love C, Liu Q, Fan A, Patel A, Smith J, Beaven A, Jima DD, Dave SS. PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas. Clin Cancer Res Feb 6

3 6. Walsh K and Kraut E. ASH Teaching Case: Paroxysmal Nocturnal Hemoglobinuria (invited). 7. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemias.ranganathan P, Yu X, Santhaanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marucci G, Blum W, Garzon R. Blood Apr 23;125(17): Doi: /blood PUBLICATIONS (Other): 1. Walsh, K., Anatomic Risk Factors for Specific Language Impairment Journal of Undergraduate Research Adams S, Green P, Claxton R, Simcox S, Williams MV, Walsh K, Leeuwenburgh C. Reactive carbonyl formation by oxidative and non-oxidative pathways Frontiers in bioscience. Aug 1; 6:A Leonard CM, Lombardino LJ, Walsh K, Eckert MA, Mockler JL, Rowe LA, Williams S, DeBose CB. Anatomical risk factors that distinguish dyslexia from SLI predict reading skill in normal children Journal of Communicative Disorders. Nov-Dec 35(6): Kazory, A., Walsh, K., Harman, E., Talor Z. Is Metformin Safe in Patients with Renal Insufficiency? Diabetes Care. Volume 30, No Walsh, K. Self Assessment in Internal Medicine: Preventive Medicine and Health Maintenance: Review Questions. June Volume 44; Number Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum B, Garzon R. Decitabine priming enhances the antileukemic effects of exportin 1(XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood Apr; 125:(17). DOI /blood Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemai: a multicenter, randomized, dose-escalation phase 1 study. Issa JP, Roboz G, Rizzieri D, Jabbour E, Stock W, O Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Lancet Oncol Sep;16(9): Doi: /S (15) Epub 2015 Aug 19. PMID: PRESENTATIONS: 2016 Resident Lecture Series at OSU: CBC 2015 Resident Lecture Series at OSU: CBC 2014 Invited Speaker at OSU ASH Highlights: MDS and MPD 2014 Medical Student Articulate Module on Eosinophilia for the Host Defense Block 2013 IM Resident Fundamentals of Medicine Conference: Oncologic Emergencies (8/13/13) 2013 IM Resident Tuesday Block Conference: Approach to patients with cytopenia (8/13/13) 2012 Local Oncology Nursing Society Meeting Speaker: CML 2012 OSU Hematology/Oncology Fellows Lecture Series: APL ABSTRACTS: 1. DM Cardona, Y Li, KJ Walsh, BA Gray, JW Lynch, RC Braylan, SZ Al-Quran. Tumor-Associated S-Phase Fraction Correlates with the Presence of c-myc Translocation in Aggressive CD10- Expressing B-Cell Lymphomas and May Predict Their Clinical Course. USCAP (United Stated and Canada Academy of Pathology) 2008 Abstract #1132: 2. Katherine Walsh, Siyao Fan, Amee Patel, Cassandra Jacobs, Jason Smith., Qingquan Liu,

4 David Rizzieri, Sandeep Dave. PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-dependent Proliferation. Blood (ASH Annual Meeting Abstracts), November 2009; 114: Jason Smith, Amee Patel, Siyao Fan, Cassandra Jacobs, Katherine Walsh, Qingquan Liu, David Rizzieri, and Sandeep Dave. Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB pathway. Blood (ASH Annual Meeting Abstracts), November 2009; 114: Katherine Walsh, Siyao Fan, Amee Patel, Cassandra Jacobs, Jason Smith, Qingquan Liu, Sandeep Dave. Hedgehog Pathway Inhibition is a Novel Therapeutic Approach in Lymphomas and Its Efficacy is Inversely Related to PI3 Kinase Inhibition. Blood (ASH Annual Meeting Abstracts), November 2010; 116: Jason Smith, Katherine Walsh, Cassandra Jacobs, Qingquan Liu, Siyao Fan, Amee Patel, and Sandeep Dave. Upregualted JAK/STAT Signaling Represents a Major Mode of Resistance to HDAC Inhibition In Lymphoma and Provides a Rationale for Novel Combination Therapy. Blood (ASH Annual Meeting Abstracts), November 2010; 116: J Zhang, V Grubor, C Love, A Banerjee, K Richards, P Miezcowski, C Dunphy, W Choi, W-Y Auv, G Srivastava, P Lugar, D Rizzieri, A Lagoo, L Bernal-Mizrachi, K Mann, C Flowers, K Naresh, A Evens, L Gordon, M Czader, J Gill, E His, Q Liu, A Fan, K Walsh, D Jima, M Luftig, T Ni, J Zhu, A Chadburn, S Levy, D Dunson, S Dave. 7. Hagop M. Kantarjian, Gail J. Roboz, David A. Rizzieri, Wendy Stock, Casey L. O'Connell, Elizabeth A Griffiths, Karen Yee, Raoul Tibes, Guillermo Garcia-Manero, Farhad Ravandi, Katherine Walsh, Eric Feldman, Ellen Ritchie, Arati Rao, Carlos Decastro, Aaron D. Schimmer, Ruben A. Mesa, Ibrahim Syed, Gavin Choy, Aram Oganesian, Pietro Taverna, Mohammad Azab, Woonbok Chung, and Jean-Pierre Issa Results From the Dose Escalation Phase of a Randomized Phase 1 2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 414. (Oral) 8. Rebecca B Klisovic, Hongyan Wang, Alison Walker, Katherine Walsh, Sumithira Vasu, Ramiro Garzon, Steven M. Devine, Jiang Wang, Celia Garr, Adam Norris, John C. Byrd, Michael R. Grever, William Blum, Kenneth K. Chan, and Guido Marcucci Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: (Poster) 9. William Blum, Rebecca B Klisovic, Alison Walker, Sebastian Schwind, Yao Jiang, Jiang Wang, Mitch Phelps, Susan Geyer, Steven M. Devine, Kathy Walsh, Sumithira Vasu, John P. Curfman, Larry Schaaf, Celia Garr, Cheryl Kefauver, John C. Byrd, Michael R. Grever, Ramiro Garzon, and Guido Marcucci. Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine. Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: Casey O Connell, Raoul Tibes, Katherine Walsh, David Rizzieri, Karen Yee, Wendy Stock, Hagop Kantarjian, Michael Savona, Elizabeth Griffiths, Patricia Kropf, Jean Pierre Issa, Sue Naim, Yong Hao, Lynne Bui, Gavin Choy, Mohammad Azab, Gail Roboz. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine And/Or Decitabine Treatment Failures With SGI-110, A Novel Second Generation Hypomethylating Agent (HMA). EHA 2013 Congress Abstract P189 (Poster Presentation)

5 PROTOCOLS: Principal Investigator: 1. OSU (open): Randomized Phase II Study of Epigenetic Priming Using Decitabine with Induction Chemotherapy in Patients with Acute Myelogenous Leukemia (AML) (A New York Cancer Consortium Study). 2. OSU (open): A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with lntermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML). Co-Investigator: 1. OSU (open): Phase I Study of the Combination of Bortezomib and Sorafenib followed by Decitabine in Elderly Patients with Acute Myeloid Leukemia. 2. OSU (open): A Phase lla, Single-Arm, Open-Label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL). 3. OSU (open): Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia. 4. OSU (closed): Phase I Study of Lenalidomide and Conventional Chemotherapy in Acute Myeloid Leukemia. 5. CALGB-11001: A Phase II Study Incorporating Sorafenib into the Therapy of Patients 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia. 6. OSU-10081: A phase 1b, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine based consolidation therapy in adult patients less than or equal to 65 years old with acute myeloid leukemia (AML) 7. CALGB-10801: A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib in Newly Diagnosed Patients with Core Binding Factor Acute Myeloid Leukemia (AML). 8. CALGB-11002: A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients 60 Years Old with Acute Leukemia (AML). 9. CALGB-10403: Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL). 10. OSU-10093: A Phase I Study of Azacitidine in Combination with MEC (mitoxantrone, etoposide, cytarabine) in relapsed and refractory acute myeloid leukemia. REVIEWER: Acta Hematologica AD HOC REVIEWER: 2013 ASH Abstract Reviewer 2012 to present MDS &AA International Foundation intermittently review recent abstracts and prepare summary in lay terms for patients and community members ADVISORY BOARDS: 2013 Invited/Participated: Incyte Regional Advisory Board for Jakafi 2013 Invited/Participated: Filgrastim Franchise National Advisory Board (6/26/13-6/27/13) 2013 Invited/Declined: Pfizer Speaker Bureau 2013 Invited/Declined: Pfizer Advisory Board at ASCO for Bosulif GRANTS (awarded): 2012 Investigator Initiated Proposal to Eisai for support with drug supply (decitabine) for potential high-risk MDS trial.

6 2012 Richard P and Marie R Bremer Medical Research Fund and William H Davis Endowment for Basic Medical Research Pilot Award (internal OSU grant for career development and research) T32 Grant during fellowship at Duke University (Hematology) GRANTS (submitted): 2013 Finalist for the V Foundation MDS Translational Research Project (One of ten programs selected to submit a full proposal) 2012 Investigator Initiated Proposal to Eisai for support with drug supply (decitabine) for potential high-risk MDS trial. Professional Development: 2015 Clerkship Director of Internal Medicine 2013 AAMC Early Career Women Faculty Professional Development Seminar 2013 MDS International Bi-annual Meeting, Berlin Germany 2012 AAMC Regional Meeting: Workshop on Qualitative Assessment 2012 AA&MDS Foundation Meeting, Bethesda MD 2011 OSU Fall Biostatistics Workshop